同步脑转移非小细胞肺癌患者肺切除术后结局
单中心回顾性分析2005至2024年86例同步脑转移非小细胞肺癌患者,行原发肺肿瘤切除联合脑转移灶根治性治疗。Cox回归显示年龄、ECOG>1、FEV1 ppo、治疗顺序及缺乏全身治疗与长期总死亡率相关。
要点
- 同步脑转移NSCLC患者行根治性肺切除联合脑转移灶治疗安全可行,5年总生存率43.4%。
- ECOG>1与长期总死亡率显著相关(HR 4.81)。
- 缺乏全身治疗与长期总死亡率显著相关(HR 2.94)。
核心结论
- 经过选择的少转移性脑转移患者行根治性治疗安全可行,可能获得可观的长期生存,尤其适用于体能状态好、肺功能好的年轻患者。
研究设计与样本
- 单中心队列研究,纳入2005至2024年86例(35例女性,51例男性)同步脑转移非小细胞肺癌患者,共113次事件,中位年龄59岁(范围52-67岁)。
主要发现
- 最常见组织学亚型为腺癌(71例,82.6%)。
- 70例(81.4%)患者优先接受脑转移灶局部治疗,包括神经外科手术(N=50)、伽玛刀放射外科(N=32)或放疗(N=4)。
- 肺手术包括肺叶切除(N=77)、全肺或双肺叶切除(N=6)和亚肺叶切除(N=3)。
- 与肺手术相关,术前接受全身治疗48例(55.8%),围手术期13例(15.1%),术后16例(18.6%)。
临床怎么用
- 对经过选择的少转移性脑转移NSCLC患者,可考虑根治性肺切除联合脑转移灶根治性治疗。
- 优先选择体能状态好、肺功能好的年轻患者进行此类根治性治疗。
- 应重视全身治疗的应用,缺乏全身治疗与长期总死亡率增加相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To report on the outcomes in a single-centre cohort of patients who underwent resection of their primary lung tumour along with radical treatment of their synchronous brain metastases. MATERIALS AND METHODS: Between 2005 and 2024, 86 patients (35 females and 51 males) with 113 events with a median age of 59 years (range: 52-67) were treated. The most common histological subtype was adenocarcinoma (71 patients, 82.6%). In 70 patients (81.4%), the local treatment for brain metastases was prioritised. This included neurosurgery (N = 50), gamma knife radiosurgery (N = 32), or radiotherapy (N = 4). Lung surgeries consisted of lobectomy (N = 77), pneumonectomy or bilobectomy (N = 6), and sublobar resection (N = 3). Related to lung surgery, systemic therapy was administered preoperatively in 48 patients (55.8%), perioperatively in 13 (15.1%) and postoperatively in 16 (18.6%). RESULTS: Ninety-day mortality was 4.6%. The 5-year overall and disease-free survival rates were 43.4% (95% CI, 33.8%-55.6%) and 32.9% (95% CI, 23.6%-45.8%), respectively. Cox regression analysis identified several preoperative variables associated with long-term overall mortality: age (years) (HR, 1.04; 95% CI, 1.01-1.07; P = .016), Eastern Cooperative Oncology Group performance status > 1 (HR, 4.81; 95% CI, 1.99-11.6; P = .002), FEV1 ppo (%) (HR, 0.98; 95% CI, 0.96-1; P = .034), local lung vs brain consolidative treatment first (HR, 2.05; 95% CI, 1.04-4.04; P = .048), and absence of systemic therapy (HR, 2.94; 95% CI, 1.30-6.65; P = .018). CONCLUSIONS: Curative-intent treatment in selected patients with oligometastatic brain involvement can be performed safely and may result in substantial long-term survival, especially in fit young patients with good pulmonary function.
引用
- Armand E, Fourdrain A, Todesco A, et al. Outcomes of Non-Small-Cell Lung Cancer Resection in Patients With Synchronous Brain Metastases. Eur J Cardiothorac Surg. 2025. PMID: 40891869. doi:10.1093/ejcts/ezaf292
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。